07X Stock Overview
A clinical stage drug platform company, develops drugs to treat neurodegeneration.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Annovis Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.35 |
| 52 Week High | US$18.10 |
| 52 Week Low | US$4.42 |
| Beta | 1.77 |
| 11 Month Change | -25.38% |
| 3 Month Change | -50.28% |
| 1 Year Change | -59.04% |
| 33 Year Change | -92.25% |
| 5 Year Change | n/a |
| Change since IPO | 13.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 07X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.1% | 4.0% | 0.09% |
| 1Y | -59.0% | -19.2% | 3.1% |
Return vs Industry: 07X underperformed the German Biotechs industry which returned -19.2% over the past year.
Return vs Market: 07X underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 07X volatility | |
|---|---|
| 07X Average Weekly Movement | 25.7% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 07X's share price has been volatile over the past 3 months.
Volatility Over Time: 07X's weekly volatility has increased from 18% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 11 | Maria Maccecchini | www.annovisbio.com |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.
Annovis Bio, Inc. Fundamentals Summary
| 07X fundamental statistics | |
|---|---|
| Market cap | €62.06m |
| Earnings (TTM) | -€44.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs 07X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 07X income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$47.53m |
| Earnings | -US$47.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 07X perform over the long term?
See historical performance and comparison